The global plasma fractionation market size is estimated to grow from USD 4.80 billion in 2024 to USD 12.7 billion by 2035, representing a CAGR of 9.2% during the forecast period till 2035.
Owing to the growing demand for plasma-derived therapies, plasma fractionators are investing in expanding their existing capabilities across various regions; of these, ~30% initiatives were undertaken in north america
During our research, we were able to identify recent expansions undertaken by plasma fractionators, during the time period.
Most of the expansions (85%) within this domain were undertaken for the establishment of new facilities. This is followed by expansion instances which involved the setup of new plants (13%). Notable examples of the plasma fractionation companies undertaking new facility initiatives (in alphabetical order) include ADMA Biologics, Biotest, Evolve Biologics, Reliance Life Sciences and Shire.
It worth highlighting that in August 2021, Bio Products Laboratory (BPL) has taken an expansion initiative to build a new sterile filling facility for plasma-derived products at Hertfordshire, UK. Further, in February 2019, Kedrion announced FDA approval for resumption of manufacturing fraction II+III, fraction V and cryo paste at New York, US.
The global installed plasma fractionation capacity is spread across various geographies; over 90% of the global installed plasma fractionation capacity is dedicated to the manufacturing of albumins and immunoglobulins for commercial applications
Over the past two decades, the global demand for plasma-derived therapies has increased significantly and is continuing to grow due to more patients being diagnosed with rare diseases, higher standards of care and broader access to various treatment options. Further, owing to higher efficacy and ability to prevent or treat severe conditions, plasma therapies are continuously being employed, resulting in the plasma fractionation capacity to increase several folds.
Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Plasma Fractionation Market.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/plasma-fractionation-market.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
+1 (415) 800 3415
Comments
0 comment